Vivos Therapeutics completed a private placement on March 31 2026 that raised $2.39 million, giving a Michigan‑based investor group a 19.9% equity stake in the company. The group, composed of SP Manager LLC, V‑CO Investors LLC, V‑CO Investors 2 LLC, and V‑CO Investors 3 LLC, paid $850,000 in cash and converted a $1.4 million bridge note to equity, bringing the total proceeds to the stated amount.
The capital is earmarked for general working capital rather than a specific expansion program. This allocation reflects the company’s need to shore up liquidity amid a period of net losses and ongoing operational investments. In the third quarter of 2025, Vivos reported revenue of $6.8 million—an increase of 76% year‑over‑year—while posting a net loss of $5.4 million. Gross margin stood at 58.0%, operating margin at –69.8%, and net margin at –79.6%, underscoring the company’s high cost base and the need for additional cash to fund growth initiatives.
The private placement is part of a broader pattern of equity financing that Vivos has relied on to support its expansion and acquisition strategy. The company’s recent acquisition of The Sleep Center of Nevada (SCN) has added to its revenue base but also introduced integration costs and a larger operating footprint. The infusion of $2.39 million provides a buffer that can be deployed to cover working‑capital needs, support the integration of SCN, and maintain the company’s ability to pursue further acquisitions or product development without immediately diluting existing shareholders more than necessary.
The investor group’s 19.9% stake gives it significant influence over corporate governance and strategic direction. The group has expressed an intention to engage with Vivos’ management and board, potentially shaping decisions on capital allocation, operational priorities, and future financing rounds. Their involvement may also signal confidence in the company’s long‑term prospects, which could help attract additional investors or partners.
Vivos has also filed a late 10‑K for the year ended December 31 2025, citing the complexity of integrating SCN. The delayed filing highlights the operational challenges the company faces as it expands its sleep‑center network. Despite these hurdles, the company remains positioned within the competitive medical‑technology market for obstructive sleep apnea, where it offers oral appliance therapy and diagnostic protocols. The capital raise, while dilutive, strengthens the balance sheet and supports the company’s strategic initiatives in a market that continues to grow.
In summary, the $2.39 million private placement provides Vivos Therapeutics with essential liquidity to manage its current operating costs and pursue growth opportunities. The transaction underscores the company’s ongoing reliance on equity financing and the strategic influence of its new major shareholder. While the capital raise will dilute existing shareholders, it also positions Vivos to navigate its integration challenges and continue expanding its sleep‑center operations in a competitive market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.